Dear collaborators,

As we approach the final week of the CovidSurg patient inclusion window we would like to thank all collaborators from across the world for their invaluable support and contribution to the study which began just four months ago. Collaborators have put in a remarkable effort which has enabled us to rapidly share patient data and inform the management of Covid-19 infected patients who underwent surgery during the pandemic.

**CovidSurg-Cancer Closing Stages**

CovidSurg-Cancer is reaching closing stages of the project. Many thanks to all collaborators who have contributed to the COVIDSurg-Cancer project to date.

**We now need to identify a team classification** (group 1 or group 2) for your specialty in your hospital to help us keep track of follow-up of patients within the study.

Please read the below carefully and identify your team classification.

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Select Group 1</td>
<td>if your team can accurately include all eligible patients included those operated, and non-operated (delayed or who had an alternative treatment) if applicable</td>
<td>Select Group 2 if your team can accurately include operated patients ONLY</td>
</tr>
<tr>
<td>Teams in group 1 will be included in analyses (and authorship) for papers both describing outcomes of operated and non-operated patients</td>
<td>Teams in group 2 will be included only in analyses (and authorship) for papers describing outcomes of operated patients</td>
<td></td>
</tr>
</tbody>
</table>

Please complete the following form to indicate your team classification:

[https://is.gd/cancerfollowup](https://is.gd/cancerfollowup)

**One form should be completed per specialty team at your hospital before 31st July 2020.**

Please find in the attached checklist the final steps for the project for Group 1 and Group 2 teams.
CovidSurg Week – Register Your Interest Today!

The CovidSurg Cohort study has demonstrated the adverse outcomes of surgery in SARS-CoV-2 infected patients. Early signals from CovidSurg-Cancer show that surgery following SARS-CoV-2 infection is associated with poor outcomes, even if surgery is several weeks after initial diagnosis. However, more granular data are needed to explore this.

GlobalSurg | CovidSurg Week is an international multi-centre prospective cohort study that aims to:

(1) determine the optimal timing for surgery in patients previously infected with SARS-CoV-2

(2) determine key global surgical indicators.

Details on the regional dissemination strategy for CovidSurg Week will feature in next week’s newsletter.

All hospitals are eligible to participate in this study, including hospitals that have not admitted SARS-CoV-2 infected patients.
Register your interest and find out more at:

GlobalSurg | CovidSurg Week.

Previous Newsletters

Past editions of the weekly CovidSurg newsletter can be found on the CovidSurg website at https://globalsurg.org/covidsurg/ (scroll to bottom of webpage)